Altimmune Inc
Biotechnology
Altimmune Inc (ALT) Stock News
The latest ALT headlines and market coverage — 10 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
HIMS & HERS HEALTH, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Law firm Kirby McInerney LLP is investigating Hims & Hers Health following an FTC lawsuit alleging the company engaged in deceptive privacy practices by sharing customers' sensitive medical information with third-party advertisers including Meta Platforms. The announcement triggered a 14.73% stock price decline on July 29, 2026.
- GlobeNewswire Inc.·
AIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC.
Aimei Health Technology Co., Ltd. announced the termination of its Business Combination Agreement with United Hydrogen Group Inc. on July 7, 2026, due to failure to close the transaction by the outside date specified in the agreement. The company expressed confidence in identifying future transaction opportunities.
- GlobeNewswire Inc.·
AMERANT INVESTMENTS APPOINTS RICARDO SUCRE TO LEAD INTERNATIONAL WEALTH MANAGEMENT BUSINESS DEVELOPMENT
Amerant Investments announced the appointment of Ricardo Sucre as Head of International Wealth Management Business Development. Sucre brings over 20 years of experience from leading financial institutions including Morgan Stanley and Bolton Global Capital. The appointment reflects Amerant's strategic focus on expanding its international wealth management platform and attracting experienced financial advisors to its integrated banking and investment services model.
- Benzinga·
UNIVERSAL HEALTH REALTY INCOME TRUST ANNOUNCES DIVIDEND INCREASE
Universal Health Realty Income Trust (NYSE:UHT) announced that its Board of Trustees voted to increase the quarterly dividend by $0.005, with a new dividend of $0.75 per share payable on June 30, 2026 to shareholders of record as of June 22, 2026.
- GlobeNewswire Inc.·
STEALTHGAS INC. Reports First Quarter 2026 Financial And Operating Results
StealthGas Inc. reported Q1 2026 net income of $15.9 million ($0.43 EPS), a 24% increase from the previous quarter, with revenues of $42.8 million. The company strengthened its liquidity to $131.2 million and secured approximately 55% of fleet days for the remainder of 2026 under period charters. Three vessel sales were completed or announced, generating approximately $26 million in proceeds. The company maintains an unlevered balance sheet with all vessels unencumbered.
- Benzinga·
SOURCE ROCK ROYALTIES ANNOUNCES FIRST QUARTER 2026 RESULTS AND PROVIDES CORPORATE UPDATE
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ CALGARY, AB , June 1, 2026 /CNW/ - Source Rock Royalties Ltd. ("Source Rock") (TSXV: SRR ), a pure-play oil and gas royalty company with an established portfolio of oil royalties and Crown mineral leases, announces results for the three-month period ended March 31, 2026 ("Q1 2026"). President's Message - Corporate Update During Q1 2026, we experienced two very different market environments. Oil prices were below $60.00 USD per barrel in January and remained very weak for almost all of February; which followed extended oil price weakness throughout the second half of 2025. These prolonged lower oil prices resulted in less new drilling activity on our royalty lands and reduced new production to offset natural declines from consistent drilling activity in 2024 and the first half of 2025. In addition, our production volume royalty had a scheduled decline from 70 bbl/d to 39 bbl/d that went into effect on January 1, 2026. This weakness reversed quickly when oil prices spiked in March, which changed the dynamic across our royalty lands for the first quarter and improved our outlook for the remainder of 2026. March royalty production rebounded from earlier in Q1 2026 to average 204 boe/d and royalty revenue for the month was approximately $623,000. Seven new horizontal wells began producing in March on our central Alberta (4) and S.E. Saskatchewan (3) royalty lands. The higher oil price environment not only increases the royalty revenue from our existing production due to our ~90% oil royalty production ratio, but it also positively changes our expectations for new drilling on our royalty lands. In particular, the operator of our Clearwater royalty lands recently disclosed that they have added a second rig to the property and anticipate an increase in the number of Clearwater horizontal wells to b
- Benzinga·
UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DIVIDEND
Universal Health Services, Inc. (NYSE:UHS) announced that its Board of Directors approved a cash dividend of $0.20 per share payable on June 18, 2026 to shareholders of record as of June 8, 2026.
- Benzinga·
METALLIUM DESCRIBES COMPANY'S METAL PROCESSING TECHNOLOGY TO COMBAT THE 'WEAPONIZATION OF THE PERIODIC TABLE' AND HALT RELIANCE ON CHINA DURING PRESENTATION AT CANACCORD GENUITY 5th ANNUAL GLOBAL METALS AND MINING CONFERENCE IN NEVADA
Metallium Limited presented its patented Flash Joule Heating (FJH) technology at the Canaccord Genuity Global Metals and Mining Conference, positioning it as a solution to reduce U.S. reliance on China for critical metals processing. The company, which recently received a Department of War grant for gallium and germanium recovery from e-waste, is pursuing a NASDAQ uplist expected later in 2026 and focusing on urban mining/recycling and mineral processing verticals.
- Benzinga·
GREY WOLF ANIMAL HEALTH REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
TORONTO , May 21, 2026 /CNW/ - Grey Wolf Animal Health Corp. (TSXV: WOLF ) ("Grey Wolf" or the "Company"), a Canadian diversified health company, today announced financial results for the three months ended March 31, 2026. Highlights Revenue for the quarter increased year over year by 10.5% to $8.8 million. Gross profit increased year over year by 13.5% to $4.7 million for the quarter. Adjusted EBITDA 1 increased year over year by 16.6% to $1.5 million for the quarter. Introducing a 5-year financial target to organically double Adjusted EBITDA 1 by the end of 2030. "We posted a solid first quarter for both revenue and Adjusted EBITDA," said Angela Cechetto, Chief Executive Officer. "Our Pharmacy business grew organically by 8.8% to $5.6 million due to an increase in sales of compounded products. Meanwhile, our Animal Health revenue grew by 13.8% to $3.1 million year-over-year resulting from an increase in sales of established products, new products introduced during the prior year and an increase in commission revenue. Adjusted EBITDA 1 for the quarter increased year-over-year by 16.6% to $1.5 million as a result of higher revenue and gross profits. During 2026, we will continue to advance our growth strategy by investing in key initiatives to support future scale, including the development of a new facility, implementation of an ERP system and continued investment in personnel." Ms. Cechetto continued, "Our five-year financial goals are grounded in a commitment to invest in our people, facilities and processes. As a result of these investments, we have set a target to organically double Adjusted EBITDA 1 by the end of 2030. We are also actively pursuing acquisition opportunities to meaningfully augment this organic growth plan over the same horizon." Key Financial Data and Comparative Results Three months ended Mar 31, 2026 Mar 31, 2025 Revenue $8,753,736 $7,921,835
- GlobeNewswire Inc.·
GE HEALTHCARE STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating GE HealthCare Technologies Inc. on Behalf of GE HealthCare Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating GE HealthCare Technologies for potential securities law violations following the company's April 29, 2026 earnings announcement. GE HealthCare missed Q1 2026 consensus EPS estimates ($0.99 vs. $1.05 expected) and reduced full-year guidance to $4.80-$5.00 from $4.95-$5.15, citing a PDx supplier issue. The stock declined 13% ($9.01 per share) on the news.